This study reports the first comparison of healthy donor subjective well-being during two alternative procedures of hematopoietic stem cells harvesting for allogeneic transplantation. Among the 105 donors included between September 1996 and October 1998 in the SFGM French randomised trial aiming to compare allogeneic bone marrow (BM) transplantation and blood cell (BC) transplantation, 64 donors (33 in BC and 31 in BM groups) were relevant for the analysis. They had received a set of self-administered questionnaires to complete during the collection process, aiming to measure anxiety (assessed using the Spielberger's State-Trait Anxiety Inventory) and pain induced by the procedure (evaluated using a visual analogical scale). Results showed that no harvest procedure is free from pain even if none was more painful than the other. Levels of anxiety before the collection procedure were high in both groups and significantly so for BC donors. Although BC collection induces at least similar levels of pain and anxiety as does BM collection, they were of a different kind, and the short-term impact of G-CSF stimulation on the well-being of BC donors has to be taken into account in improving quality of care in the allogeneic setting. Bone Marrow Transplantation (2002) 29, 145-149. DOI: 10.1038/sj/bmt/1703338 Keywords: healthy donors; hematopoietic stem cell harvest; anxiety; pain; allogeneic transplantation Blood cell transplantation (BCT) is now the standard for autologous transplant:
Blood cell transplantation (BCT) is now the standard for autologous transplant:
1 the main arguments in favour of substituting this procedure for classical bone marrow transplantation (BMT) in the autologous setting were quicker haematological recovery, decrease in related cost 2, 3 and easier progenitor collection associated with an increased acceptability of the BC collection procedure by patients. 4 Research is currently ongoing to determine if these advantages of BCT can be extended to the allogeneic setting. [5] [6] [7] The Société Française de Greffe de Moëlle (SFGM) recently published the preliminary results of a prospective trial in France comparing allogeneic BCT vs BMT in patients with early-stage leukaemia, which showed that BCT was associated with a dramatic improvement in both platelet and neutrophil reconstitution and was a less costly procedure when taking into account both the grafting procedure and the first 6 months of follow-up. 8 However, these benefits were also associated with the occurrence of more severe chronic graft-versus-host disease (GVHD), and longer follow-up is still needed to assess the impact of chronic GVHD on relapse, survival and quality of life.
A problem which is specific to the allogeneic setting, concerns the impact of alternative stem cell harvesting procedures on healthy HLA-identical donors. Apheresis can be expected to be a less invasive procedure than the classical bone marrow harvest, because it does not necessitate general anaesthesia, red cell transfusion or hospitalisation but it may have a specific short-term impact on the well-being of healthy donors. Analysis of the impact on healthy donors of the collection procedure was therefore included as one of the secondary objectives of the SFGM prospective trial, by taking into account not only tolerance and toxicity associated with G-CSF administration and apheresis for BCT donors and bone marrow harvest for BMT donors, but also anxiety, pain and discomfort subjectively experienced by both groups of healthy donors during the course of these procedures. Results are presented below.
Donors and methods

Donors included in the psychometric survey
Between September 1996 and October 1998, a multicenter randomised trial aiming to compare allogeneic blood cell (BC) transplantation and allogeneic bone marrow (BM) transplantation was conducted in 17 centres affiliated with the SFGM. The protocol was reviewed by the Comité Con-sultatif de Protection des Personnes dans la Recherche Biomédicale (CCPRB) of Marseilles and all the 111 couples of patients/donors included had to give informed consent. The primary end point of this trial was to compare the time to reach unsupported platelet counts greater than 25 × 10 9 platelets/l in the two groups. Among the secondary objectives also studied (other parameters of platelet reconstitution, neutrophil recovery, acute GVHD, chronic GVHD as well as the cost of the process and quality of life of recipients), the impact on donors was considered. Selfadministered questionnaires during the collection procedures including validated psychometric scales were used to measure anxiety and pain experienced by normal sibling donors. A total of 14 out of 17 centres had agreed to participate in this specific substudy. Among the 105 donors included in these centres, 70 donors had filled in at least one questionnaire (answer rate = 67%). Sixty-four donors (33 in the BCT and 31 in the BMT groups) were relevant for the analysis because they had completed the questionnaire administered before the collection procedures (necessary to have the baseline levels of pain and the 'Trait Anxiety') and at least one of the others. We found no statistical difference in terms of age and sex between the donors included in the study and those not included.
BM harvesting and BC collection methods
BM was collected under general anaesthesia: the donor was hospitalised the evening before the harvest and was generally discharged from hospital the day after.
BC donors received lenograstim (Granocyte, kindly provided by Chugaï Rhône-Poulenc-Rhorer, Gentilly, France), at 10 g/kg/day as one subcutaneous injection in the late afternoon for 5 days (day 1 to day 5), four injections before the first apheresis and one after the first collection. Apheresis was performed as an outpatient process on 2 consecutive days (day 5 and day 6, per protocol), beginning 12 to 18 h after the fourth G-CSF injection. Day 6 (second apheresis) was timed to coincide with day 0 of the allograft recipient. If necessary, in order to reach a minimum of 6 × 10 6 CD34 + cells/kg recipient body weight, a third apheresis was performed on day 7 after an additional lenograstim injection on day 6. The first apheresis product was conserved at 4°C overnight and fresh products were reinjected the day of the second apheresis (day 0) without further manipulation. Occasionally, the third product was reinfused on day 1.
Psychometric measures of the impact of collection procedures on donor well-being
Donors were informed verbally about the aim of the psychometric study and gave informed consent. Each donor who agreed to participate in the study received a set of selfadministered questionnaires to complete during the collection process.
In the BC group, each donor successively received four self-administered questionnaires at different points of time during the collection procedure: before the initiation of the collection procedure, ie before the first injection of G-CSF; before the first apheresis (after five injections of G-CSF, on day 5); during the course of the first apheresis (while stem cells were being collected, on day 5); and after completion of the whole process (on day 6 or 7).
In the BM group, each donor received three self-administered questionnaires, successively: before the collection process, ie the day before the BM harvest; during the BM harvest (the anesthesist, directed by the donor, filled in the pain visual analogical scale as soon as the donor had woken up); and after the BM harvest, about 4 h after the donor had woken up.
The main parameters considered relevant for evaluation of donor's actual experience during stem cell collection were the following.
Anxiety was assessed using the French version of Spielberger's State-Trait Anxiety Inventory. 9, 10 This 40-item instrument measures both the subject's generic profile towards anxiety ('Trait Anxiety', 20 items, with a score ranging from 20 to 80) and individual's anxiety when confronted with a specific situation ('State Anxiety', 20 items, score also ranging from 20 to 80).
Pain induced by the process was measured using the visual analogical scale (VAS). This non-graduated scale, which is a simple horizontal line, has a length of 10 cm: zero corresponds to 'no pain at all' and 10 to 'worst possible pain'. The donor is asked to place a mark along the line to indicate his/her subjective judgement about intensity of pain he/she is suffering. The score is obtained by measuring the distance between the left extremity of the line and the patient's mark.
In addition, specific questions about the frequency of three types of symptoms potentially associated with G-CSF stimulation (headaches, bone and muscular pain), the level of severity of these symptoms as well as the level of discomfort associated to them (using four-point scales: not at all, a little bit, quite a bit, very much) were included in the second questionnaire proposed to the BC group.
Self-administered questionnaires also included questions about donor socio-demographic characteristics, how they subjectively anticipated the collection procedure, and if they were satisfied or not by explanations given by the medical team (14 questions in total). At the end of the process they were also asked for their general opinion about the procedure (by using a four-point scale: easy, quite easy, quite difficult, difficult). Timing of the psychometric measures is described in Table 1 .
Statistical analysis
Statistical analysis was carried out with the SPSS software (SPSS, version 8). Non-normality of distributions was established using the Kolmogorov-Smirnov test. The nonparametric Mann-Whitney test was used to test significant differences between groups for quantitative data (anxiety scores, pain scores, age). The chi-square test was used to test significant differences between groups for qualitative data. Significant changes over time of anxiety and pain scores were tested using the non-parametric Wilcoxon test for paired series. Correlations between age and pain and anxiety scores were calculated by the rho of Spearman. Level of significance was fixed at 0.05. 
Results
Donor characteristics
The majority (56%) of donors were males, were living in couples (77%), had children (67%) and were currently employed (88%). However, only a minority (39%) had a level of education equal or superior to high-school certificate. No significant differences were found between BC and BM donors for these socio-demographic characteristics. BM donors were, however, older (mean age = 39 ± 10) than BC donors (34 ± 8) (P = 0.02). This difference has no consequence on our results since we have verified that correlation coefficients between age and pain and anxiety scores in our population were very low.
Anxiety
As expected, we found no statistical difference between 'Trait Anxiety' scores of either group of patients (mean scores ± s.d. = 39 ± 9 in BC donors vs 39 ± 11 in BM donors). Levels of 'State Anxiety' before the collection procedure were higher in the BC (45 ± 29) than in the BM group (35 ± 13): this difference reached statistical significance at the 10% level (P = 0.055). These levels did not differ between groups (32 ± 8 vs 29 ± 9 in BC and BM, respectively) when donors were interviewed after the end of each collection procedure, and had significantly decreased between pre-and post-procedures (P Ͻ 0.01 for all statistics) for both BC and BM donors. Interestingly, state anxiety had already started to significantly decrease for BC donors when measured in the course of the apheresis procedure (36 ± 10) in comparison with pre-procedure baseline level. The great majority of donors, 73% in the BC group (90% in the BM group, respectively P = NS) declared afterwards that the collection procedure had been 'quite' or 'very' easy for them. Similarly, 93% of donors in both groups declared that they had been 'quite' or 'very' satisfied by the explanations given to them by the medical team during the course of the collection procedure. Table 2 shows that the pain experienced by donors did not follow the same pattern according to the procedure. At inclusion, the levels of pain are logically quite low in both groups and none of the donor group experienced a more significant level of pain than the other. In the BC group, the maximum pain experienced by donors happened during G-CSF stimulation (mean score on VAS = 32 mm ± 28, P Ͻ 0.05 when compared to other measures of pain during the harvest procedure) and pain persisted during the first apheresis (25 ± 25). In the BM group, the peak of pain was experienced after recovery from anaesthesia (23 ± 19). When comparing the highest pain scores, we found no statistical difference between either group. Table 3 presents the specific symptoms experienced during G-CSF stimulation that were described and assessed by BC donors. A total of 28/33 donors (85%) reported at least one symptom, while 10/33 and 10/33, respectively, reported two or three symptoms simultaneously. About one out of three donors who experienced headaches or bone pain, and one out of five who had muscular pain, declared that pain associated with each of these symptoms was 'quite' or 'very' severe. However, fewer donors considered that these symptoms, and their associated pain, were 'quite a bit' or 'very much' disturbing for them, and none of the donors asked to stop the procedure. Bone Marrow Transplantation
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Discussion
The aim of our study was to report the first comparison of healthy donor subjective well-being during two different procedures of hematopoietic stem cell harvesting for allogeneic transplantation. This comparison was carried out by using validated psychometric instruments: the visual analogical scale (VAS) is considered as one of the most sensitive among the various methods for measuring pain; 11 Spielberger's 9 scale has been proven to be a very effective tool for distinguishing between anxiety which is related to the individual's psychological personality (Trait-Anxiety) and that (State-Anxiety) which is generated by the individual's confrontation with a specific, potentially stressful, situation such as undergoing a harvesting procedure in the context of allogeneic transplantation for a family member. The 64 healthy donors who participated in our study responded precisely to the questionnaires, without assistance, as a guarantee of true self-assessment. Previous studies had already shown that there may be some disparity between the physician's estimations and a patient's selfassessment of treatment side-effects and experience. 12 Some limitations of our study must be acknowledged. In the group of donors who experienced BM harvest, the last measurement of pain occurred soon after recovery from anaesthesia, and it would have been interesting to repeat such a measurement a few days later in order to assess how long it persisted after surgery, and then to have an idea not only on the intensity, but also on duration of this pain. Another criticism could be that our sample consisted of a limited number of donors who participated in the randomised trial which was the basis of our study (answer rate: 67%): this is due to the logistic difficulties induced by the fact that this study necessitated the administration of questionnaires to donors at precise times. We noticed that no donor had refused in participate to the study. As the proof that the donors included were a representative sample, we found no statistical difference in terms of age and sex between the donors included in the study and those not included.
The first result of our study is that no harvest procedure is free of pain and anxiety for healthy donors. Concerning the pain, we chose to focus our analysis on comparing maximum levels experienced during both harvest procedures. In the BM group, not surprisingly, the maximum pain experienced by donors followed the surgery itself when donors recover from general anesthaesia. Although a lot of clinical studies had already reported on the toxicity of G-CSF for healthy donors, [13] [14] [15] [16] none had evaluated the impact of G-CSF stimulation on subjective well-being. Our study confirms that G-CSF stimulation is the most painful part of the harvesting procedure for BC donors and cytapheresis generated only moderate pain. When comparing the highest levels of pain, we showed neither harvest procedure was more painful than the other.
Levels of anxiety before the collection procedure were fairly high in both groups of donors. This result is in accordance with a prior psychological study conduced on BC donors only. 17 Such high anxiety before the procedure did not appear to be due to lack of information and communication with medical staff, since nearly all donors declared themselves satisfied by the explanations given to them by the medical team. It was probably mainly due to an a priori fear of the harvesting procedure itself, more than to the prospect of the graft to be performed for the donor's sister or brother. Indeed, the State Anxiety scores of donors decreased regularly during the course of both collection procedures and became very low as soon as the procedures had been completed, while at the same time the recipient was receiving the allograft. Moreover, BC collection appeared to generate higher levels of anxiety before the procedure than did BM harvest, perhaps due to the uncertainty of the long-term effects of administered G-CSF.
It must, however, be emphasised that the inconvenience generated by both harvesting procedures was subjectively limited in the donors' experience, suggesting that the symbolic dimension of gift and familial solidarity involved in allogeneic transplantation [18] [19] [20] partly compensates for the pain, discomfort and psychological stress which is generated by the technical medical procedures that donors have to undergo. Although a majority of BC donors experienced pain and painful symptoms during G-CSF stimulation, only a few of them considered this situation to have induced significant levels of discomfort. In both groups of donors, the great majority of donors felt, after having completed the collection procedure, that it had been an 'easy' process for them.
In spite of recent reassuring reports on this matter, 21 one of the major uncertainties for substituting BCT for BMT in the allogeneic setting for patients with early-stage leukaemia remains the potential long-term deleterious effects of G-CSF administration to healthy donors. Our study suggests that BC collection induces at least similar levels of pain and anxiety as BM collection although of a different kind, and that the short-term impact of G-CSF stimulation on the well-being of BC donors has also to be taken into account for improving quality of care in the allogeneic setting.
